Navigation Links
Plants could pave the way for new ovarian cancer treatments
Date:8/25/2011

Tropical plants may contain the basis of new and effective treatments for ovarian cancer, according to researchers at the Universities of Strathclyde and Portsmouth.

The scientists are developing a programme for testing plant extracts for the ability to stop cells from ovarian tumours growing. In initial tests, several plant extracts killed the tumour samples, taken from cancer patients.

The extracts are complex mixtures of many different chemicals but ingredients in the plants could be used as starting points for new medicines to tackle the disease. The scientists are now planning further investigation of the most promising compounds.

Ovarian cancer is the fifth most common cancer in women, affecting more than 6,500 in the UK alone each year. It is also one of the most deadly, killing more than 4,000 women in the UK annually, despite survival rates nearly doubling in the past 30 years.

The research is an example of the pioneering work of the Strathclyde Institute of Pharmacy and Biomedical Sciences in developing new medicines for illnesses and conditions including infectious diseases, cancer, heart disease, and schizophrenia. An 8 million fundraising campaign is underway for the Institute's new 36 million building, to expand and enhance its innovative research and education in medicine discovery, development and use.

Alan Harvey, Professor of Pharmacology at Strathclyde Institute of Pharmacy and Biomedical Sciences, said: "Ovarian cancer's inherent danger to women's health is compounded by the fact that it is notoriously difficult to detect. The disease's high death rates urgently need to be dealt with through safe and potent new treatments.

"Our collection of natural plant samples gives us a broad range of possibilities for treatment and we have had good results from many plants. A great many samples have been studied in our collaboration with Portsmouth and a lot of activity has been detected that wouldn't have been picked up in conventional tests.

"The high throughput screening in the method we have used has produced a high return and we are hoping that more tests will bring new treatments a step closer."

Ian Cree, Professor of Histopathology, Pharmacy and Biomedical Sciences at Portsmouth's Institute of Biomedical and Biomolecular Science and Director of the Cancer Laboratory at Queen Alexandra Hospital, said: "This is a first no one has managed to use cells obtained directly from cancers to screen an entire library of plant extracts and we are very excited by the results obtained.

"The key now will be to obtain further funding to produce drugs from those samples showing that they can kill cancer cells.

"It should be remembered that drug development is a very lengthy process and that these results, though exciting, are a long way from being used in patients."


'/>"/>

Contact: Media and Corporate Communications
corporatecomms@strath.ac.uk
44-014-154-84123
University of Strathclyde
Source:Eurekalert

Related medicine news :

1. Wayne State researcher receives NSF award to develop neural implants
2. Elimination of national kidney allocation policy improves minority access to transplants
3. Half-matched transplants widen pool of donors for leukemia and lymphoma
4. Study of phytoremediation benefits of 86 indoor plants published
5. FDA: Breast Implants Basically Safe, But Wont Last a Lifetime
6. Wireless tags give physicians details and condition of orthopedic implants with the wave of a wand
7. Liver-cell transplants show promise in reversing genetic disease affecting liver and lungs
8. Study confirms link between breast implants and rare form of cancer
9. Enhanced cord blood stem cell transplants safe in long-term studies
10. Long-term study shows that kidney transplants are faring better than previously reported
11. EPA Proposes Tougher Air Pollution Rules for Power Plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... TopConsumerReviews.com recently gave a best-in-class 5 ... , The healthcare industry in the United States has undergone major changes over the ... needing to have a doctor’s order to get a blood test or other lab ...
(Date:8/16/2017)... ... August 16, 2017 , ... Women’s Excellence in ... pain. In addition to oncology services, the new center will specialize in ... heavy bleeding during menstruation), uterine fibroids, and uterine and pelvic adhesions (scar tissue). ...
(Date:8/16/2017)... ... August 16, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, Prache ... effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , “Prache ...
(Date:8/16/2017)... ... ... Chain”: an inspirational story for those shackled by the chains of a broken life. ... writer and a woman of great faith and wisdom. She is a great motivational ... born and raised in Vero Beach, Florida and has dedicated her life and ministry to ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... ... of disease. It’s reaching out to a patient who feels isolated. It’s developing ... amid madness. , WesternU President Daniel R. Wilson, MD, PhD, invited three renowned ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... as president, effective Aug. 7, 2017. ... to pursue other interests and will serve as president emeritus ... has served us in multiple leadership roles since he joined ... 2015 and has provided decisive, strategic leadership which continues to ...
(Date:8/3/2017)... -- Opioid addiction and other drugs of abuse, blood poisoning ... outcomes, were problems taken on directly as laboratory professionals, ... them, met this week. This according to Kalorama Information. ... abuse, procalcitonin and acute kidney injury were key focuses ... in San Diego, CA.  Mechanisms ...
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
Breaking Medicine Technology: